Suppr超能文献

重组人凝血因子VIII的药代动力学及种间缩放

Pharmacokinetics and interspecies scaling of recombinant human factor VIII.

作者信息

Mordenti J, Osaka G, Garcia K, Thomsen K, Licko V, Meng G

机构信息

Genentech, Inc., South San Francisco, California 94080, USA.

出版信息

Toxicol Appl Pharmacol. 1996 Jan;136(1):75-8. doi: 10.1006/taap.1996.0008.

Abstract

Recombinant human (rh) factor VIII is a glycoprotein consisting of multiple polypeptides with relative mobilities (M(r)) ranging from 80,000 to 210,000. It is produced in mammalian cells. Single-dose intravenous pharmacokinetic studies were conducted with rh factor VIII (Kogenate rh Antihemophilic Factor, Miles, Inc.) in male mice (21.0-25.8 g) and rats (252.0-254.2 g). Each species received 400 IU/kg, and blood was collected up to 12 hr (mice) or 32.5 hr (rats) post-dose. Immunoreactive factor VIII concentrations in plasma were quantified by a sensitive and specific ELISA. In both species, the disposition profiles were described by the sum of two exponentials. The pharmacokinetics of rh factor VIII in mouse were as follows: clearance, 27.7 ml/hr/kg; initial volume of distribution, 72 ml/kg; steady-state volume of distribution, 148 ml/kg; and terminal half-life, 4.1 hr. In rat, the mean estimates were as follows: clearance, 16.0 ml/hr/kg; initial volume of distribution, 41 ml/kg; steady-state volume of distribution, 125 ml/kg; and terminal half-life, 5.5 hr. These pharmacokinetic parameters for rh factor VIII in animals and human rh factor VIII pharmacokinetic parameters from the literature were evaluated to determine if the parameters can be represented by the allometric relationship, Y = aWb, where Y is the pharmacokinetic parameter, and W is body weight. The following allometric relations were obtained for rh factor VIII: clearance (ml/hr) = 10.4W0.69, half-life (hr) = 7.5 W0.18, initial volume of distribution (ml) = 43.6 W1.04, and steady-state volume of distribution (ml) = 99.1 W0.84. The allometric exponents for each parameter conformed to theory and were within the range of values commonly observed for xenobiotics and therapeutic proteins. These studies suggest that the pharmacokinetics of rh factor VIII in laboratory animals are predictive of the disposition in humans despite the complex nature of its biological interactions and the chemical diversity of the purified material.

摘要

重组人(rh)因子VIII是一种糖蛋白,由多种相对迁移率(M(r))在80,000至210,000之间的多肽组成。它在哺乳动物细胞中产生。用rh因子VIII(科跃奇rh抗血友病因子,迈尔斯公司)对雄性小鼠(21.0 - 25.8克)和大鼠(252.0 - 254.2克)进行了单剂量静脉药代动力学研究。每个物种接受400 IU/kg的剂量,并在给药后长达12小时(小鼠)或32.5小时(大鼠)采集血液。通过灵敏且特异的ELISA对血浆中免疫反应性因子VIII浓度进行定量。在两个物种中,处置曲线均由两个指数之和描述。rh因子VIII在小鼠体内的药代动力学参数如下:清除率,27.7 ml/hr/kg;初始分布容积,72 ml/kg;稳态分布容积,148 ml/kg;以及末端半衰期,4.1小时。在大鼠中,平均估计值如下:清除率,16.0 ml/hr/kg;初始分布容积,41 ml/kg;稳态分布容积,125 ml/kg;以及末端半衰期,5.5小时。对动物体内rh因子VIII的这些药代动力学参数以及文献中的人rh因子VIII药代动力学参数进行了评估,以确定这些参数是否可以用异速生长关系Y = aW^b来表示,其中Y是药代动力学参数,W是体重。对于rh因子VIII得到了以下异速生长关系:清除率(ml/hr) = 10.4W^0.69,半衰期(hr) = 7.5W^0.18,初始分布容积(ml) = 43.6W^1.04,以及稳态分布容积(ml) = 99.1W^0.84。每个参数的异速生长指数符合理论,并且在异生素和治疗性蛋白质常见的值范围内。这些研究表明,尽管rh因子VIII的生物相互作用性质复杂且纯化材料的化学多样性高,但实验室动物体内rh因子VIII的药代动力学可预测其在人体内的处置情况。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验